Key result
High urgency heart transplantation for refractory electrical storm in patients with severe left ventricular dysfunction was associated with a 69% 1-year survival rate.
Why the study?
Does heart transplantation improve survival in patients with refractory electrical storm and severely impaired ventricular function?
Does heart transplantation improve survival in patients with refractory electrical storm and severely impaired ventricular function?
Answers are grounded in this paper and cite their sources.
Heart transplantation may serve as a rare bail-out therapy for refractory electrical storm in patients with severely impaired left ventricular function, despite substantial post-operative mortality.
Refractory electrical storm (ES) is associated with extreme mortality.1–7 It is known that the sympathetic nervous system is a key player for this life-threatening condition.1,2 Specific treatment of ES often requires ICD reprogramming, antiarrhythmic drug therapy, sedation, mechanical ventilation, catheter ablation, autonomic modulation, and mechanical circulatory support.1–3 Importantly, deep sedation and mechanical ventilation is often indicated to reduce psychological distress and to reduce pro-arrhythmogenic sympathetic tone.1–3,8 In addition to beta-blockers therapy, percutaneous ganglionic stellate blockade, thoracic epidural anaesthesia, or left cardiac sympathetic denervation might be used to treat malignant ventricular arrhythmia.6,7 Catheter ablation should be considered in patients with incessant monomorphic ventricular tachycardia (VT) (if haemodynamically tolerated) or in the presence of ventricular fibrillation-triggering premature ventricular complexes.2 The latest ESC guideline clearly states that the underlying aetiology determines further management.1,2 Patients with severely impaired ventricular function including patients who are listed for cardiac transplantation have a very high risk to suffer sudden cardiac death (SCD) and ES. Thus, it is recommended to implant an ICD for primary prevention of SCD in these patients. The present study by Martins et al. included 45 patients who received high urgency heart transplantation within 9 days due to refractory ES.9 Importantly, the mean left ventricular ejection fraction was 25%. About 91% patients had already an ICD, half of them implanted as secondary prevention. Thirty-two patients (71%) had a history of ventricular arrhythmia, and 27% had a previous history of ES. After transplantation, 20/45 patients needed immediate haemodynamic support by extracorporeal membrane oxygenation. Of note, in-hospital mortality rate after transplantation was 28.9%. One-year survival was 69%. The authors concluded that refractory ES is a rare indication for lifesaving heart transplantation, although post-operative mortality was substantial in this cohort of patients.9 As stated in the discussion by Martins et al., only few case reports were published regarding heart transplantation in ES.10–12 In those reports, and in clear contrast to the present report, all patients survived after heart transplantation. The present study, however, is the largest to describe the clinical characteristics, follow-up, and outcomes of patients undergoing heart transplantation as a treatment for refractory ES. Importantly, it was shown that 1-year survival rate is lower in ES (69%) compared to other transplantation cohorts (85%).9 The study by Martins et al. is interesting since the latest SCD guidelines 2023 do not make clear recommendation about heart transplantation as a rescue strategy in ES.2 The ESC guideline makes general statements for patients prior to heart transplant: ‘In patients awaiting heart transplantation, ICD implantation for primary prevention should be considered’ (Class: IIa C). Furthermore, ‘In patients awaiting heart transplantation, a wearable cardiac defibrillator may be considered’ (Class IIb C). Post-heart transplant, the ESC guidelines recommend: ‘In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD implantation may be considered’ (Class IIb).2 Thus, the present ESC guideline 2023 does not mention the option of heart transplantation in patients with refractory malignant ventricular arrhythmia. However, in 2009 the ACC/AHA guidelines for acute heart failure state recurrent life-threatening left ventricular arrhythmias despite an implantable cardiac defibrillator, antiarrhythmic therapy, or catheter-based ablation as an indication for heart transplantation.13 The latest ESC guidelines 2021 on heart failure state advanced heart failure as the indication for heart transplantation.14 Therefore, the study by Martins et al. is important because they describe for the first time quite a large group of patients who received heart transplantation due to refractory ES. Nevertheless, all of the patients in the study by Martins et al. had significant left ventricular dysfunction (25%) and the majority of patients was in cardiogenic shock. These aspects need to be considered if the concept of heart transplantation as a bail-out therapy in ES is considered. The study has limitations, since the rate of catheter ablation attempts was limited. Catheter ablation was performed in 20% of all included patients only. It remains unclear if a higher rate of VT ablation could have influenced prognosis.2 The impact of other mechanical treatment was not assessed.4 In conclusion, Martins et al. must be congratulated for the bravery to perform this study. They show that heart transplantation might be an option in refractory ES if all established interventions for ES failed. However, none of the reported patients had a normal left ventricular function, which must be considered. Thus, severely impaired LV function plus ES triggered heart transplantation in the present study and not the presence of an ES per se in an otherwise normal heart. Thus, it might be ‘too stormy’ to consider heart transplantation in any patient with ES. The lack of donor organs will also prohibit that this rare bail-out option is more frequently used in patients with ES. Nevertheless, Martins et al. contribute with their findings to this important medical field,9 which still has substantial knowledge gaps.15,16 This study was supported by EU Grant Horizon 2020 MAESTRIA Consortium; grant number 965286.
No takes yet. Share an insight, caveat, or question.
Andreas Goette (2023) conducted an editorial in Refractory electrical storm (n=45). High urgency heart transplantation vs. Other transplantation cohorts was evaluated on 1-year survival. High urgency heart transplantation for refractory electrical storm in patients with severe left ventricular dysfunction was associated with a 69% 1-year survival rate.
Synapse has enriched 10 related papers. Consider them for comparative context: